Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 11, 1998, Pages 3826-3831

  Comaru Schally, Ana Maria ^a,b   Brannan, William ^a   Schally, Andrew V ^a   Colcolough, Maureen ^a   Monga, Manoj ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; GONADORELIN ANTAGONIST;

AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SCORING SYSTEM; SEXUAL FUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL; URINE FLOW RATE;

EID: 0031790128     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.11.3826     Document Type: Article

References (41)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. 1984 The development of human benign prostatic hyperplasia with age. J. Urol. 132:474-479.
2. Tsang KK, Garraway WM. 1993 Impact of benign prostatic hyperplasia on general well-being of men. Prostate. 23:1-7.
3. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. 1997 Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol. 157:1711-1717.
4. Oesterling JE. 1996 Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate. 6(Suppl):67-73.
5. Isaacs JT. 1990 Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate. 3(Supl):1-7.
6. Roehrbom CG. 1995 The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am. 22:445-453.
7. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. 1995 New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med. 155:477-481.
8. Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson J-E. 1997 Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology. 50:214-220.
9. Shapiro E, Lepor H. 1995 Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am. 22:285-287.
10. Barry M, Roehrborn C. 1997 Management of benign prostatic hyperplasia. Annu Rev Med. 48:177-189.
11. de Bellis A, Ghiandi P, Comerci A, et al. 1996 Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-α in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab. 81:4148-4154.
12. Steiner MS. 1995 Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol. 153:1085-1096.
13. Culig Z, Hobisch A, Cronauer MV, et al. 1996 Regulation of prostatic growth and function by peptide growth factors. Prostate. 28:392-405.
14. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. 1994 Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab. 79:1410-1415.
15. Begun FP, Story MT, Hopp KA, Shapiro E, Lawson RK. 1995 Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol. 153:839-843.
16. Tammela T. 1997 Benign prostatic hyperplasia. Practical treatment guidelines. Drugs Aging. 10:349-366.
17. McKiernan JM, Lowe FC. 1997 Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J. 90:509-513.
18. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV. 1988 New antagonists of LH-RH. II. Inhibition and potentiation of LH-RH by closely related analogues. Int J Pept Protein Res. 32:425-435.
19. Schally AV, Comaru-Schally AM. 1997 Hypothalamic and other peptide hormones. In: Holland JF, Frei III E, Bast Jr RC, Kufe DE, Morton DL, Weichselbaum RR, eds. Cancer medicine, 4th ed. Baltimore: Williams & Wilkins; 1067-1085.
20. Reissmann TH, Engel J, Kutscher B, et al. 1994 Cetrorelix. Drugs Future. 19:228-237.
21. Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, et al. 1995 Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45:275-281.
22. Gonzalez-Barcena D, Bañuelos-Alvarez R, Perez-Ochoa E, et al. 1997 Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist cetrorelix. Hum Reprod. 12:2028-2035.
23. Schally AV, Comaru-Schally AM. 1997 Rational use of agonists and antagonists of luteinizing hormone-releasing (LH-RH) in the treatment of hormone-sensitive neoplasms and gynecologic conditions. Adv Drug Deliv Rev. 28:157-169.
24. Lepor H, Williford WO, Barry MJ, et al. 1996 The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:533-539.
25. 7) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 29:231-240.
26. Wein AJ. 1995 Assessing treatment results in benign prostatic hyperplasia. Urol Clin North Am. 22:345-355.
27. Reynolds III CF, Frank E, Thase ME, et al. 1988 Assessment of sexual function in depressed, impotent, and healthy men: factor analysis of a brief sexual function questionnaire for men. Psychiatry Res. 24:231-250.
28. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, et al. 1994 Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate. 24:84-92.
29. Jungwirth A, Schally AV, Pinski J, et al. 1997 Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer. 75:1585-1592.
30. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P. 1997 Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:839-845.
31. Nickel JC, Fradet Y, Boake, RC, et al. 1996 Efficacy and safety of Finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). Can Med Assoc J. 155:1251-1259.
32. Ezz El Din K, Kiemeney LALM, de Wildt MJAM, Debruyne FMJ, de la Rosette JJMCH. 1996 Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology. 48:393-397.
33. Kaplan SA, Te AE. 1995 Uroflowmetry and urodynamics. Urol Clin North Am. 22:309-320.
34. Witjes WPJ, Wijkstra H, Debruyne FMJ, de la Rosette JJMCH. 1997 Quantitative assessment of uroflow: is there a circadian rhythm? Urology. 50:221-228.
35. McConnell JD, Bruskewitz R, Walsh P, et al. 1998 The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:557-563.
36. Walsh PC. 1996 Treatment of benign prostatic hyperplasia. N Engl J Med. 335:586-587.
37. Boyle P, Gould AL, Roehrbom CG. 1996 Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 48:398-405.
38. Peters CA, Walsh PC. 1987 The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 317:599-604.
39. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. 1989 Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab. 69:629-632.
40. McConnell JS, Wilson JD, George FW, Geller J, Pappas F, Stoner E. 1992 Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 74:505-508.
41. Farmer A, Noble J. 1997 Drug treatment for benign prostatic hyperplasia-decreasing muscle tone within the prostate gland may be more effective than reducing the size of the prostate. Br Med J. 314:1215-1216.